Neuromyelitis Optica Spectrum Disorder Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Global Neuromyelitis Optica (NMOSD) Market is segmented by treatment (monoclonal antibody drugs, immunosuppressive agents, plasma exchange therapy, and other treatments), and geography (North America, Europe, Asia-Pacific, and rest of the world). The report offers the value (in USD million) for the above segments.

Neuromyelitis Optica Spectrum Disorder Market Size

Single User License
Team License
Corporate License
Book before:
Neuromyelitis Optica Spectrum Disorder Market Summary
share button
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 6.20 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Neuromyelitis Optica Spectrum Disorder Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

OFF

Team License

OFF

Corporate License

OFF
Book before:

Neuromyelitis Optica Spectrum Disorder Market Analysis

The neuromyelitis optica spectrum disorder market is projected to register a CAGR of 6.2% during the forecast period.

  • The COVID-19 pandemic had a severe impact on various markets, and its direct consequences have been multifaceted. While demand declined in some healthcare industries, several markets remain intact and may offer promising growth opportunities. The global COVID-19 outbreak and lockdown scenarios in various countries resulted in the shutdown of hospitals and clinics to prevent the spread of the SARS-CoV-2 virus. 
  • According to an article published by the National Center for Biotechnology Information (NCBI) in 2021, titled "The impact of COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany," there was a significant drop in multiple sclerosis and neuromyelitis optica spectrum disorder patient hospitalizations during the different pandemic periods in 2020, with the greatest reduction occurring during the pandemic's initial wave. The delayed or interrupted treatment due to the pandemic is thus increasing the risk of relapse in patients. With resumed services and procedures, hospital visits have increased, leading to an increase in demand for treatment over the forecast period.
  • Several factors are propelling the growth of the market, including the increasing incidence and prevalence of neuromyelitis optica spectrum disorder (NMOSD), rising demand for better treatment options, increasing research and development activities, and product approvals. According to a research article published in the American Academy of Neurology in 2021, the highest estimates of the incidence and prevalence of NMOSD in the Afro-Caribbean region were 0.73 per 100,000 person-years and 10/100,000 persons, respectively.
  • Furthermore, increasing research and development activities and product approvals by companies are also contributing to the growth of the market. For instance, in June 2021, Mitsubishi Tanabe Pharma Corporation received approval for UPLIZNA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in Japan. However, the high cost of therapy for neuromyelitis optica is projected to stifle market expansion.

Neuromyelitis Optica Spectrum Disorder Market Trends

Monoclonal Antibody Drugs Segment Expects to Register a High CAGR in the Forecast Period

  • The monoclonal antibody drugs segment is expected to dominate the market due to its high efficacy and tolerability in treating autoimmune diseases, including neuromyelitis optica spectrum disorder. In this disorder, B cells produce auto-antibodies, secrete cytokines/chemokines, and interact with T cells, playing a pathogenic role. As a result, monoclonal antibody-mediated B cell depletion has emerged as a viable treatment option for NMOSD. Notable monoclonal antibody drugs for treating NMOSD include Rituximab, Inebilizumab, Tocilizumab, Satralizumab, and Eculizumab.
  • Furthermore, the market growth is driven by the increasing approvals of monoclonal antibody drugs and the growing research and development activities by the industry players to develop more effective treatment options for patients with NMOSD. 
  • For instance, in November 2021, the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) authorized Horizon's UPLINZA as a monotherapy for treating adult patients with NMOSD who test positive for anti-aquaporin-4 immunoglobulin G (AQP4-IgG+) antibodies. Additionally, in June 2022, Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. received approval for Anti-CD20 Monoclonal Antibody Rituxan for preventing the recurrence of neuromyelitis optica spectrum disorder.
  • In summary, the increasing efficacy and tolerability of monoclonal antibody drugs, rising product approvals, and research and development activities by the market players are driving the growth of this segment, which is expected to further propel the market growth over the forecast period.
Neuromyelitis Optica Spectrum Disorder Market: Number of Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Trials, As of February 2023, By Phase, Global

North America is Expected to Have the Significant Market Share

  • North America holds a significant market share in the neuromyelitis optica spectrum disorder (NMOSD) treatment market, owing to several factors. One of the primary drivers of market growth in the region is the increasing incidence and prevalence of NMOSD. According to the National Center for Biotechnology Information, approximately 15,000 people in the United States were affected by this disorder in 2021.
  • Additionally, the region's well-established healthcare infrastructure and availability of efficient treatment methods also contribute to the market growth. Moreover, non-profit organizations' financial assistance programs and increasing research and development activities in the region further support the growth of the market. For example, The Patient Access Network (PAN) Foundation launched a new financial assistance program in November 2021 to support individuals living with NMOSD.
  • Furthermore, recent product approvals and increasing research and development activities in the region are also driving the market's growth. In May 2022, Alexion announced positive results for the open-label Phase III CHAMPION-NMOSD trial of ULTOMIRIS (ravulizumab-cwvz). The study showed a positive impact on relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD compared to the external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial.
  • In conclusion, the increasing prevalence of NMOSD, rising research and development activities, and product approvals are expected to fuel the growth of the NMOSD treatment market in North America in the near future.
Neuromyelitis Optica Spectrum Disorder Market - Growth Rate by Region

Neuromyelitis Optica Spectrum Disorder Industry Overview

The neuromyelitis optica spectrum disorder market is moderately competitive, with a large number of players present in the market. Companies in this space are focusing on adopting various business strategies such as collaborations, acquisitions, and product approvals to maintain their market position. Key players in this market include Hoffmann-La Roche Ltd, Horizon Therapeutics plc, TG Therapeutics, Opexa Therapeutics, and Mitsubishi Tanabe Pharma.

Neuromyelitis Optica Spectrum Disorder Market Leaders

  1. Hoffmann-La Roche Ltd

  2. TG Therapeutics

  3. Opexa Therapeutics

  4. Mitsubishi Tanabe Pharma

  5. Horizon Therapeutics plc (Viela Bio)

*Disclaimer: Major Players sorted in no particular order

Neuromyelitis Optica Spectrum Disorder Market Concentration
bookmark Need More Details on Market Players and Competitors?
Download PDF

Neuromyelitis Optica Spectrum Disorder Market News

June 2022: the Brazilian Health Regulatory Agency (ANVISA) also approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who test positive for the AQP4-IgG biomarker.

May 2022: UPLIZNA, a drug developed by Horizon Therapeutics, was approved by the European Commission as a monotherapy for treating adult patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD). This approval applies to all adult NMOSD patients, regardless of whether they test positive or negative for the AQP4-IgG biomarker.

Neuromyelitis Optica Spectrum Disorder Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Neuromyelitis Optica Spectrum Disorder

      2. 4.2.2 Increasing Research and Development Activities, Product Approvals and Rising Demand for Better Treatment Options

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Therapy for Neuromyelitis Optica Spectrum Disorder

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment

      1. 5.1.1 Monoclonal Antibody Drugs

      2. 5.1.2 Immunosuppressive Agents

      3. 5.1.3 Plasma Exchange Therapy

      4. 5.1.4 Other Treatments

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Rest of the World

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Hoffmann-La Roche Ltd

      2. 6.1.2 Horizon Therapeutics plc (Viela Bio)

      3. 6.1.3 AstraZeneca

      4. 6.1.4 Mitsubishi Tanabe Pharma

      5. 6.1.5 Harbour BioMed

      6. 6.1.6 RemeGen

      7. 6.1.7 Teva Pharmaceutical Industries Ltd

      8. 6.1.8 Horizon Therapeutics plc

      9. 6.1.9 TG Therapeutics

      10. 6.1.10 Opexa Therapeutics

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Neuromyelitis Optica Spectrum Disorder Industry Segmentation

As per the scope of the report, neuromyelitis optica spectrum disorder is an autoimmune disorder in which white blood cells and antibodies attack and damage the optic nerve, resulting in discomfort and visual loss, spinal cord causing paralysis, loss of sensation in the legs and arms, and problems with bladder and bowel function. 

The neuromyelitis optica spectrum disorder market is segmented by treatment (immunosuppressive agents, plasma exchange therapy, and other treatments) and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). 

The report offers the value (in USD million) for the above segments.

By Treatment
Monoclonal Antibody Drugs
Immunosuppressive Agents
Plasma Exchange Therapy
Other Treatments
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
customize-icon Need A Different Region Or Segment?
Customize Now

Neuromyelitis Optica Spectrum Disorder Market Research FAQs

The Neuromyelitis Optica Spectrum Disorder Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)

Hoffmann-La Roche Ltd, TG Therapeutics, Opexa Therapeutics, Mitsubishi Tanabe Pharma and Horizon Therapeutics plc (Viela Bio) are the major companies operating in the Neuromyelitis Optica Spectrum Disorder Market.

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Neuromyelitis Optica Spectrum Disorder Market.

The report covers the Neuromyelitis Optica Spectrum Disorder Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Neuromyelitis Optica Spectrum Disorder Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Neuromyelitis Optica Industry Report

Statistics for the 2023 Neuromyelitis Optica market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Neuromyelitis Optica analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Neuromyelitis Optica Spectrum Disorder Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)